China Pharma Innovation Hinges On Participation Of Medical Experts – SFDA Drug Registration Director
This article was originally published in PharmAsia News
China approves less than 10 new chemical entities annually, according to SFDA Director of Drug Registration Wei Zhang, who has urged healthcare professionals to join China’s innovation efforts.
You may also be interested in...
China Drug Approvals Up 26%, Mostly Due To Generics
China's State FDA increased drug approvals by more than 26% in 2010, with the boost largely due to an increase in generic drug approvals. The agency also cleared more clinical trials for drugs that treat diseases that have a large societal impact, according to SFDA's second annual report on the status of drug approvals
China Could Be Third Entry For Idiopathic Pulmonary Fibrosis Drug Pirfenidone
SHANGHAI - Tokyo-headquartered GNI announced its Shanghai-based subsidiary-Shanghai Genomics has submitted a new drug application to Shanghai FDA for its TNF modulator F647 (pirfenidone) to treat patients with idiopathic pulmonary fibrosis (IPF)
China Roundup: Rare Disease Approvals, Local mRNA Shots, CEO Visits
AstraZeneca and CANbridge obtain new approvals for their rare disease drugs in China, where a new domestic mRNA vaccine is also being made available amid a new wave of COVID infections. Meanwhile, the CEOs of pharma and other companies pay visits, showing China remains high on their list of global priorities.